Nkarta (Nkarta) Earnings per Share (Diluted) : $-2.35 (TTM As of Mar. 2024)

View and export this data going back to 2020. Start your Free Trial

What is Nkarta Earnings per Share (Diluted)?

Nkarta's Earnings per Share (Diluted) for the three months ended in Mar. 2024 was $-0.58. Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2024 was $-2.35.

Nkarta's EPS (Basic) for the three months ended in Mar. 2024 was $-0.58. Its EPS (Basic) for the trailing twelve months (TTM) ended in Mar. 2024 was $-2.35.

Nkarta's EPS without NRI for the three months ended in Mar. 2024 was $-0.58. Its EPS without NRI for the trailing twelve months (TTM) ended in Mar. 2024 was $-2.35.

During the past 3 years, the average EPS without NRIGrowth Rate was 7.70% per year. During the past 5 years, the average EPS without NRI Growth Rate was -71.40% per year.

During the past 6 years, Nkarta's highest 3-Year average EPS without NRI Growth Rate was 7.70% per year. The lowest was -262.50% per year. And the median was -1.40% per year.

Nkarta Earnings per Share (Diluted) Historical Data

The historical data trend for Nkarta's Earnings per Share (Diluted) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Nkarta Earnings per Share (Diluted) Chart

Nkarta Annual Data

Trend

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Earnings per Share (Diluted)

Get a 7-Day Free Trial

-2.35

-5.44

-2.62

-2.61

-2.40

Nkarta Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Earnings per Share (Diluted)	Get a 7-Day Free Trial															-0.63	-0.68	-0.52	-0.57	-0.58

Competitive Comparison of Nkarta's Earnings per Share (Diluted)

For the Biotechnology subindustry, Nkarta's PE Ratio, along with its competitors' market caps and PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Nkarta's PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Nkarta's PE Ratio distribution charts can be found below:

* The bar in red indicates where Nkarta's PE Ratio falls into.

Nkarta Earnings per Share (Diluted) Calculation

Earnings Per Share (EPS) is the amount of earnings per outstanding share of the company's stock. In calculating earnings per share, the dividends of preferred stocks need to subtracted from the total net income first.

Nkarta's Earnings Per Share (Diluted) for the fiscal year that ended in Dec. 2023 is calculated as

Diluted Earnings Per Share (A: Dec. 2023 )	=	(Net Income	-	Preferred Dividends)	/	Shares Outstanding (Diluted Average)
	=	(-117.501	-	0)	/	49.014
	=	-2.40

Nkarta's Earnings Per Share (Diluted) for the quarter that ended in Mar. 2024 is calculated as

Diluted Earnings Per Share (Q: Mar. 2024 )	=	(Net Income	-	Preferred Dividends	/	Shares Outstanding (Diluted Average)
	=	(-29.518	-	0)	/	50.682
	=	-0.58

Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-2.35

Companies also reported diluted shares in their financial reports. Diluted shares include the shares of convertibles or warrants outstanding.

Nkarta (NAS:NKTX) Earnings per Share (Diluted) Explanation

Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.

Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.

Nkarta Earnings per Share (Diluted) Related Terms

Thank you for viewing the detailed overview of Nkarta's Earnings per Share (Diluted) provided by GuruFocus.com. Please click on the following links to see related term pages.

Nkarta (Nkarta) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Nkarta Inc (NAS:NKTX) » Definitions » Earnings per Share (Diluted)

Comparable Companies

Traded in Other Exchanges

N/A

Address

6000 Shoreline Court, Suite 102, South San Francisco, CA, USA, 94080

Website

https://www.nkartatx.com

Nkarta Inc is a biopharmaceutical company engaged in developing engineered natural killer (NK) cells to treat cancer. The Company is engaged in leveraging the natural potent power of NK cells to identify and kill abnormal cells and recruit adaptive immune effectors to generate responses that are specific and durable. The company is combining its NK expansion platform technology with proprietary cell engineering technologies to generate an abundant supply of NK cells, engineer enhanced NK cell recognition of tumor targets, and improve persistence for sustained activity in the body for the treatment of cancer. The Company's operations are based in South San Francisco, California.

Executives

Paul J Hastings	director, officer: See Remarks	61 HARTFORD STREET, SAN FRANCISCO CA 94114
David Shook	officer: Chief Medical Officer	6000 SHORELINE COURT, SUITE 102, SOUTH SAN FRANCISCO CA 94080
Alicia J. Hager	officer: Chief Legal Officer	C/O ONCOMED PHARMACEUTICALS, INC., 800 CHESAPEAKE DRIVE, REDWOOD CITY CA 94063
Ralph Brandenberger	officer: Sr. VP, Technical Operations	6000 SHORELINE COURT, SUITE 102, SAN FRANCISCO CA 94080
James Trager	officer: Chief Scientific Officer	6000 SHORELINE COURT, SUITE 102, SOUTH SAN FRANCISCO CA 94080
Alyssa Levin	officer: See Remarks	6000 SHORELINE COURT, SUITE 102, SOUTH SAN FRANCISCO CA 94080
Nadir Mahmood	officer: Chief Business Officer	6000 SHORELINE COURT, SUITE 102, SOUTH SAN FRANCISCO CA 94080
Simeon George	director	161 WASHINGTON STREET, SUITE 500, CONSHOHOCKEN PA 19428
Ra Capital Healthcare Fund Lp	10 percent owner	200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116
Angela Thedinga	director	C/O ADVERUM BIOTECHNOLOGIES, INC., 1035 O'BRIEN DRIVE, MENLO PARK CA 94025
Ra Capital Nexus Fund, L.p.	director, 10 percent owner	200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116
Kanya Rajangam	officer: Chief Medical Officer	C/O SENTI BIOSCIENCES, INC., 2 CORPORATE DRIVE, FIRST FLOOR, SOUTH SAN FRANCISCO CA 94080
Ra Capital Management, L.p.	10 percent owner	200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116
Plc Glaxosmithkline	director, 10 percent owner	980 GREAT WEST ROAD, BRENTFORD MIDDLESEX X0 TW8 9GS
Novo Holdings A/s	10 percent owner	TUBORG HAVNEVEJ 19, HELLERUP G7 2900